Carregant...
Profile of infliximab in the treatment of pediatric Crohn’s disease
In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the grow...
Guardat en:
| Publicat a: | Pediatric Health Med Ther |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683274/ https://ncbi.nlm.nih.gov/pubmed/29388577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PHMT.S64943 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|